Pfizer Inc. (NYSE:PFE) Shares Sold by SRS Capital Advisors Inc.

SRS Capital Advisors Inc. lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 15.9% during the fourth quarter, Holdings Channel reports. The firm owned 8,324 shares of the biopharmaceutical company’s stock after selling 1,579 shares during the period. SRS Capital Advisors Inc.’s holdings in Pfizer were worth $240,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Briaud Financial Planning Inc acquired a new position in shares of Pfizer in the 3rd quarter valued at $30,000. GoalVest Advisory LLC boosted its position in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. purchased a new stake in shares of Pfizer during the 3rd quarter worth $34,000. VisionPoint Advisory Group LLC boosted its position in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners purchased a new stake in shares of Pfizer during the 4th quarter worth $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of several research analyst reports. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research note on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Morgan Stanley lifted their price target on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday. Finally, Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus target price of $36.00.

Pfizer Stock Performance

NYSE:PFE traded up $0.11 during trading hours on Friday, reaching $27.81. 60,568,852 shares of the stock were exchanged, compared to its average volume of 41,900,304. The stock has a market capitalization of $157.48 billion, a P/E ratio of -463.42, a P/E/G ratio of 1.18 and a beta of 0.63. The firm has a 50 day simple moving average of $26.88 and a 200-day simple moving average of $28.25. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same period last year, the business posted $1.23 earnings per share. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.36 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a $0.42 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.04%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.